Ivacaftor / Tezacaftor: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PBAC (Australia) and SMC (Scotland) recommended or restricted ivacaftor / tezacaftor, while TLV (Sweden) did not recommend it.
Assessment has run over 5.2 years, from 24 Apr 2019 at ZIN (Netherlands) to 24 Jul 2024 at AWMSG (Wales).
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for ivacaftor / tezacaftor by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 15 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
ZIN (Netherlands) was first to assess ivacaftor / tezacaftor, on 24 Apr 2019; AWMSG (Wales) did not open a file until 24 Jul 2024 — a wide spread of 5.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 15 dated records fall in 2021 alone.
4 of the 7 agencies here assessed ivacaftor / tezacaftor more than once, G-BA (Germany) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for ivacaftor / tezacaftor.
The full ledger for ivacaftor / tezacaftor reads 5 recommended, 4 no benefit, 3 advice and 2 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 24 Jul 2024 | in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation… | accepted | source |
| AWMSG (Wales) | 24 Jul 2024 | Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis … | excluded, NICE appraised | source |
| ZIN (Netherlands) | 21 Dec 2021 | GVS-advies extra uitbreiding bijlage 2-voorwaarden tezacaftor ivacaftor (Symkevi®) in combinatie met ivacaftor (Kalydeco… | advice published (GVS) | source |
| HAS (France) | 30 Jun 2021 | Listing (Transparency Committee) | SMR substantial · ASMR III | source |
| TLV (Sweden) | 21 May 2021 | Symkevi ingår inte i högkostnadsskyddet | rejection or exclusion | source |
10 further decisions for ivacaftor / tezacaftor, across 5 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- ivacaftor — same ATC class R07A — Other respiratory
- elexacaftor / ivacaftor / tezacaftor — same ATC class R07A — Other respiratory
- ivacaftor / lumacaftor — same ATC class R07A — Other respiratory
- empagliflozin — also decided by SMC in 2024Q3
- ivosidenib — also decided by SMC in 2024Q3
- lenacapavir — also decided by SMC in 2024Q3
Coverage: 15 decisions for ivacaftor / tezacaftor from 7 agencies, 2019 to 2024. Data to 7 Sep 2026. ATC class R07A — Other respiratory. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.